A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects with Advanced Solid Tumors
- First Posted Date
- 2024-12-16
- Last Posted Date
- 2024-12-19
- Target Recruit Count
- 180
- Registration Number
- NCT06736327
- Locations
- 🇨🇳
JILIN Cancer Hospital, Jilin, China
A Phase 1 Study of SKB571 in Subjects with Advanced Solid Tumors
- First Posted Date
- 2024-12-10
- Last Posted Date
- 2024-12-10
- Target Recruit Count
- 138
- Registration Number
- NCT06725381
A Study of SKB264 in Combination with Pembrolizumab Versus Chemotherapy in Combination with Pembrolizumab As First-Line Treatment for PD-L1 Negative Patients with Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-12-02
- Last Posted Date
- 2024-12-02
- Target Recruit Count
- 432
- Registration Number
- NCT06711900
- Locations
- 🇨🇳
Shanghai Oriental Hospital, Shanghai, China
The Purpose of This Study is to Determine the Safety, Tolerability, and Pharmacokinetics of Brexpiprazole Long-acting Injection Following a Single Administration in Healthy Subjects/Patients With Schizophrenia.
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-05
- Last Posted Date
- 2024-11-07
- Target Recruit Count
- 56
- Registration Number
- NCT06674694
- Locations
- 🇨🇳
Beijing Anding Hospital Capital Medical University, Beijing, Beijing, China
A Study of SKB264 in Combination with Osimertinib Versus Osimertinib in Patients with Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-01
- Last Posted Date
- 2024-11-01
- Target Recruit Count
- 420
- Registration Number
- NCT06670196
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- First Posted Date
- 2024-06-07
- Last Posted Date
- 2024-06-07
- Target Recruit Count
- 406
- Registration Number
- NCT06448312
- Locations
- 🇨🇳
Shanghai Oriental Hospital, Shanghai, China
A Study of SKB518 in Patients With Advanced Solid Tumors
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2024-06-27
- Target Recruit Count
- 150
- Registration Number
- NCT06428331
Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2024-12-12
- Target Recruit Count
- 376
- Registration Number
- NCT06081959
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, China
SKB410 for Injection in Solid Tumors
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-06-27
- Target Recruit Count
- 276
- Registration Number
- NCT05906537
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2023-08-08
- Target Recruit Count
- 356
- Registration Number
- NCT05870319
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
© Copyright 2024. All Rights Reserved by MedPath